🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Placebo

    Milestone Pharmaceuticals

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  2. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  3. Placebo

    Allergan Pharmaceuticals International Limited

    Gastroparesis

    phase 3 small molecule terminated

    3 trials

  4. Placebo

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  5. Placebo

    Laboratoire HRA Pharma

    Leber congenital amaurosis (LCA)

    phase 3 small molecule active

    1 trial

  6. Placebo

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Erectile Dysfunction

    phase 3 small molecule completed

    1 trial

  7. Placebo

    Biogen

    Multiple Sclerosis, Remittent Progressive

    phase 3 small molecule completed

    1 trial

  8. Placebo

    Takeda

    Male Subjects With Chronic Constipation

    phase 3 small molecule completed

    1 trial

  9. Placebo

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  10. Placebo

    Takeda

    Lennox Gastaut Syndrome (LGS)

    phase 3 small molecule completed

    1 trial

  11. Placebo (Metoprolol succinate), Metoprololsuccinat STADA® 47,5 mg Retardtabletten, Aficamten, DOBUTAMINE , Placebo (Aficamten)

    Cytokinetics (Ireland) Limited

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  12. Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE

    Dompe' Farmaceutici S.p.A.

    Atopic Keratoconjunctivitis

    phase 3 small molecule active

    1 trial

  13. Placebo (for alirocumab)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  14. Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  15. Placebo (inhalation powder capsules) containing 1 of 4 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg or 640 µg ), TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Hypertension Associated with Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  16. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  17. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  18. Placebo - Staloral birch, oromucosal solution, STALORAL Birke 10 IR/ml und 300 IR/ml, Lösung zur Anwendung in der Mundhöhle, STALORAL Birke 300 IR/ml, Lösung zur Anwendung in der Mundhöhle

    Allergen

    Birch Pollen-induced Allergic Rhinoconjunctivitis

    phase 3 small molecule active

    1 trial

  19. Placebo - film-coated tablets, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer

    phase 3 small molecule active

    1 trial

  20. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  21. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  22. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  23. Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

    Sanofi-aventis Healthcare Pty Ltd

    Fabry Disease

    phase 3 small molecule active

    1 trial

  24. Placebo Colchicine 0.5 mg tablets, Colchicine Tiofarma 0,5 mg, tabletten

    Disc Medicine

    Aortic Valve Calcification, Inflammation, Calcification, Aortic Valve Disease, Cardiovascular Diseases, Aortic Valve Stenosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources